2. As of noon trading, Myriad Genetics ( MYGN) is down $0.48 (-1.6%) to $30.02 on light volume. Thus far, 405,824 shares of Myriad Genetics exchanged hands as compared to its average daily volume of 2.1 million shares. The stock has ranged in price between $29.92-$30.83 after having opened the day at $30.83 as compared to the previous trading day's close of $30.50.

Myriad Genetics, Inc., a molecular diagnostic company, focuses on the development and marketing of predictive medicine, personalized medicine, and prognostic medicine tests primarily in the United States. Myriad Genetics has a market cap of $2.4 billion and is part of the services sector. Shares are up 11.9% year to date as of the close of trading on Monday. Currently there are 5 analysts that rate Myriad Genetics a buy, 1 analyst rates it a sell, and 7 rate it a hold.

TheStreet Ratings rates Myriad Genetics as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, increase in stock price during the past year, impressive record of earnings per share growth and compelling growth in net income. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full Myriad Genetics Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

If you liked this article you might like

The Value of an Overvalued Market: Cramer's 'Mad Money' Recap (Thursday 8/10/17)

Kraft Heinz Takes a Page From Weight Watchers, Inks Oprah for Product Line

Weight Watchers' New CEO Mindy Grossman Says Diversity Yields Long-Term Business Success